Skip to main content
Premium Trial:

Request an Annual Quote

Baxter to Use GenOdyssee's Protein Platform for Hemophilia Research

NEW YORK (GenomeWeb News) — Protein therapy products maker GenOdyssee today said it will provide Baxter with its technology, intellectual property, and integrated processes.
 
Under the agreement, Baxter will use these platforms to discover "novel blood clotting factors" in the course of its hemophilia research, and will develop and market any "commercially viable products" resulting from the partnership.
 
Financial terms of the agreement were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.